首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 98 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTC |
| Uniprot No | P35070 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-111aa |
| 氨基酸序列 | DGNSTRSPET NGLLCGDPEE NCAATTTQSK RKGHFSRCPK QYKHYCIKGR CRFVVAEQTP SCVCDEGYIG ARCERVDLFY |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant Betacellulin: Production and Biological Activity in Diabetic Models"**
- **作者**: Yamamoto K, et al.
- **摘要**: 研究通过大肠杆菌表达系统生产重组BTC蛋白，验证其在体外和糖尿病小鼠模型中促进β细胞增殖和胰岛素分泌的作用，为糖尿病治疗提供潜在策略。
2. **"Structural and Functional Characterization of Recombinant Human Betacellulin"**
- **作者**: Shing Y, et al.
- **摘要**: 通过哺乳动物细胞系统表达并纯化重组人BTC蛋白，解析其与EGFR/ErbB受体结合的结构特征，揭示其在细胞迁移和组织修复中的功能机制。
3. **"Betacellulin Enhances Wound Healing through EGFR Signaling Pathway Activation"**
- **作者**: Li H, et al.
- **摘要**: 利用重组BTC蛋白处理皮肤创伤模型，证明其通过激活EGFR信号通路加速上皮细胞增殖和伤口愈合，提示其临床应用于慢性溃疡治疗的潜力。
4. **"Recombinant BTC Protein Induces Pancreatic Regeneration in Chronic Pancreatitis"**
- **作者**: Zhang Q, et al.
- **摘要**: 在慢性胰腺炎动物模型中，注射重组BTC蛋白可激活胰腺干细胞分化并恢复外分泌功能，为胰腺疾病再生治疗提供实验依据。
(注：上述文献信息为示例，实际引用需根据具体论文调整。)
**Background of BTC Recombinant Proteins**
BTC (B7-H4 Cross-Linking Chimeric Antigen Receptor) recombinant proteins are engineered molecules designed to enhance targeted immunotherapy, particularly in cancer treatment. They originate from advancements in CAR-T (Chimeric Antigen Receptor T-cell) therapy, which reprograms a patient’s T-cells to recognize and attack cancer cells. BTC focuses on the B7-H4 antigen, a transmembrane protein overexpressed in various cancers (e.g., breast, ovarian, lung) but minimally present in healthy tissues. This antigen plays a role in immune evasion by suppressing T-cell activity, making it a promising therapeutic target.
The recombinant protein structure typically includes an extracellular antigen-binding domain (e.g., single-chain variable fragment, scFv) specific to B7-H4. a transmembrane domain for stability, and intracellular signaling domains (e.g., CD28 or 4-1BB co-stimulatory motifs combined with CD3ζ activation domains). This design enables T-cells to recognize B7-H4-positive tumors, activate robust immune responses, and persist longer in the hostile tumor microenvironment.
Preclinical studies highlight BTC’s potential in targeting solid tumors, which are often resistant to conventional CAR-T therapies due to their immunosuppressive microenvironments. In vitro and animal models demonstrate enhanced tumor cell lysis and reduced tumor growth. However, challenges remain, including on-target/off-tumor toxicity risks and variable antigen density across tumors. Current research focuses on optimizing receptor affinity, improving safety profiles, and exploring combination therapies (e.g., checkpoint inhibitors). Clinical trials are underway to validate efficacy and safety in humans, positioning BTC recombinant proteins as a next-generation tool in precision oncology.
×
